$TVRD News

Why Is Tvardi Therapeutics Stock Falling Thursday?

Raymond James Upgrades Tvardi Therapeutics to Outperform, Announces $10 Price Target

Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript

Why Is Tvardi Therapeutics Stock Gaining Tuesday?

BTIG Reiterates Buy on Tvardi Therapeutics, Maintains $15 Price Target

Tvardi Therapeutics Announces Phase 1 Results For TTI-109, Next-Gen STAT3 Inhibitor; Co. Plans To Advance TTI-109 Into STAT3-Driven Dermatologic And Gastrointestinal Diseases, Subject To Additional Funding

HC Wainwright & Co. Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $9

Tvardi Therapeutics Q1 EPS $(0.73) Beats $(0.74) Estimate

Tvardi Therapeutics Files Prospectus For Offering $200M Mixed Shelf

Barclays Downgrades Tvardi Therapeutics to Underweight, Lowers Price Target to $3

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Barclays Maintains Equal-Weight on Tvardi Therapeutics, Lowers Price Target to $4

Piper Sandler Maintains Neutral on Tvardi Therapeutics, Lowers Price Target to $3

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Tvardi Therapeutics Q4 EPS $(0.78) Misses $(0.68) Estimate

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate

Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights

Tvardi Therapeutics Provides Updates From Phase 2 REVERT IPF Clinical Trial Of TTI-101 In Idiopathic Pulmonary Fibrosis

Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now